Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07307794Phase 1Recruiting

To Evaluate the Adhesion of TK-254RX on Healthy Participants

Role: collaborator

NCT06866613Phase 3Completed

Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.

Role: collaborator

NCT06871046Phase 3Completed

Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions

Role: collaborator

All 3 trials loaded